Listen
IRICRYN (bimatoprost) - Open-angle glaucoma, ocular hypertension
Opinions on drugs -
Posted on
Dec 05 2024
Reason for request
Initial inclusion
Summary of opinion
Favourable opinion for reimbursement in the treatment of chronic open-angle glaucoma or the treatment of ocular hypertension.
No clinical added value compared to the reference medicinal product already available (LUMIGAN 0.3 mg/mL, bimatoprost, eye drops, solution in single-dose containers).
Clinical Benefit
| Substantial |
The clinical benefit of IRICRYN (bimatoprost) 0.3 mg/mL eye drops solution, is substantial in the MA indication. |
Clinical Added Value
| no clinical added value |
This medicinal product is a hybrid that does not provide any clinical added value (CAV V) compared to the reference medi-cinal product. |
Documents
English version
Contact Us
Évaluation des médicaments
